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ABSTRACT 
Microemulsions (ME) have been proved to increase the cutaneous absorption of both lipophilic and hydrophilic medicaments when 
compared to conventional vehicles (emulsions, pure oils, aqueous solutions). Hence the aim of the present investigation is to prepare, 
characterize and optimize microemulsion of Itraconazole (ITZ). Itraconazole is an anti fungal agent, most widely used in the 
ringworm infection. It is classified as class III drug as per BCS classification. It indicates lower permeability through the skin. 
Therefore the objective of the research is to improve permeability of Itraconazole through the skin. The microemulsion was prepared 
using eucalyptus oil, tween 20 and methanol as the oil phase, surfactant and co-surfactant respectively. Pseudo-ternary phase 
diagrams were constructed to find out the optimum ratio of oil: Smix (surfactant: Co-Surfactant): water. A 3
2 full factorial design was 
applied to the optimization of the prepared microemulsion. The microemulsion was evaluated for globule size, zeta potential, in-vitro 
diffusion study etc. Results of globule size measurements and zeta potential indicated ME7 had high stability than other formulation 
of the microemulsion. For the optimization transdermal flux and %Q6 was selected as dependant variables. Results of optimization 
study also revealed ME 7 as optimized microemulsion for high permeability to the skin. Further ME7 was compared to marketed 
Itraconazole preparation (ITASPORE) and evaluated using similarity factor F2. Results of F2 value was not near to 100 indicated 
there is no similarity in diffusion profiles of ME7 and ITASPORE. Hence, indirectly it suggests there was increased in permeability 
of drug by preparing microemulsion. 
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INTRODUCTION 
The incidence of superficial fungal infections of skin, 
hair, and nails has been increased in worldwide. It has 
been estimated that about 40 million people have 
suffered from fungal infections in developing and under 
developed nations. The progression of fungal infections 
can be rapid and serious due to compromising with 
immune function. Dermatophytes are one of the most 
frequent causes of tinea and onychomycosis. Candida 
infections are also among the most widespread 
superficial cutaneous fungal infections
1
.  
Topical treatment of fungal infections has several 
superiorities including, targeting the site of infection, 
reduction of the risk of systemic side effects, 
enhancement of the efficacy of treatment and, high 
patient compliance. The efficiency of the topical 
antifungal treatment depends on the penetration of drugs 
through the target tissue. Different type of topical 
effective antifungal compounds has been used in the 
treatment of a variety of dermatological skin infections. 
The main classes of topical anti-fungal are polyenes, 
azoles, and allylamine/benzyl amines. Currently, these 
antifungal drugs are commercially available in 
conventional dosage forms such as creams, gels, lotions, 
capsule, shampoo, ointment 
2,3
. 
Development of alternative approaches for the topical 
treatment of fungal infections of skin encompasses new 
carrier systems for approved and investigational 
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compounds. Delivery of antifungal compounds into the 
skin can be enhanced with the carriers including 
colloidal systems (Microemulsions, Micelles, 
Nanoemulsion), vesicular carriers (Liposomes, 
Ethosomes, Niosomes, and Transfersomes), and 
Nanoparticles. Current dosage form available for the 
treatment of ringworm has some limitation & side 
effects like skin irritation, drug contamination. The 
current dosage form in the market has also poor patient 
compliance 
4
. Microemulsion (ME) is prepared to 
improve penetration & Bio-availability of Itraconazole. 
Topical microemulsion drug delivery can be defined as 
the application of a drug containing formulation to the 
skin to directly treat the cutaneous disorder. Fast-acting 
& There is less risk of serious adverse effects and 
limited drug interactions.  Topical microemulsion 
includes enhancing the solubility of drugs, high 
thermodynamic stability, and ease of preparation. ME 
dosage forms increase penetration enhancing ability as 
compared to other dosage forms 
1, 5-7
. 
Itraconazole (ITZ) is an effective used to treat fungal 
infections. Conventional dosage forms of Itraconazole 
showed about 15-20% bioavailability. It has a biological 
half-life of 6 hours. Itraconazole is included in Class III 
as per biopharmaceutical classification system of drugs. 
It showed low permeability hence it showed low 
bioavailability in systemic circulation via the topical 
route of administration. Hence, it is required to 
formulate a newer drug delivery system with the 
improved permeability of Itraconazole 
8-13
.  
The main purpose of the present research work was to 
develop microemulsion based drug delivery system of 
anti-fungal agent Itraconazole via topical route. With 
enhanced permeation drug targets the site. The 
microemulsion was optimized using 3
2
 full factorial 
designs. For optimization % of oil and Smix was selected 
as independent variable while transdermal flux and % 
Q6 was selected as the dependent variable. Statistical 
optimization was done using MLRA and desirability 
analysis. 
MATERIALS AND METHODS 
Materials 
Itraconazole was obtained as gift sample from Astron 
Research Center, Ahmedabad.  Eucalyptus oil, 
Methanol, Tween-20, Isopropyl Alcohol was procured 
from S. D. Fine Chemicals, Mumbai, India. All other 
solvents used for the analytical purpose was obtained 
from Sigma Aldrich, Mumbai, India. All the solvents 
used were of analytical HPLC grade. 
Experimental Methods 
Solubility study 
To find out the suitable oil which can be used as the oil 
phase in the microemulsion, the solubility of 
Itraconazole in various oils, surfactants, and co-
surfactants was indicated in Table 1. An excess amount 
of Itraconazole was added in 2.0mL of the selected oil, 
surfactant, and co-surfactant in stoppered vials (capacity 
2.0 mL) and then preliminary mixing was carried out 
over magnetic stirrer for few minutes. Later on, these 
vials were kept in a mechanical bath shaker for 72 hours 
at 37±0.5C. The equilibrated samples were then 
centrifuged at 10,000 rpm for 10 minutes. The 
supernatant was separated, filtered, and after appropriate 
dilution with methanol, solubility was determined by 
UV-visible spectrophotometer 
3
. 
Construction of pseudo-ternary phase diagrams 
Microemulsion consists of three components namely 
Oil, Water and Surfactant & Co-surfactant. The aqueous 
phase and concentration of co-solvent is varied and 
continued addition of water in this system results in the 
formation of Microemulsion. Hence, the pseudo-ternary 
diagram can be formed.In order to find out the 
concentration range of components for the existing 
range of microemulsion pseudo-ternary phase diagram 
was constructed using the water titration method. 
Ternary plots were constructed using Eucalyptus oil, 
Tween-20, Methanol as oil, surfactant, and co-surfactant 
using different ratios of (Smix) Surfactants to Co-
surfactants were prepared (1:1, 1:2, 2:1, 3:1) with both 
the oils; respectively. For each phase diagram the ratio 
of oil to Smix were varied as (9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 
3:7, 2:8, and 1:9 % w/w). The mixtures of oil and Smix at 
certain weight ratios were diluted with water, under 
moderate stirring. After being equilibrated, the mixtures 
were assessed visually and determined as a 
microemulsion or coarse emulsions. The phase diagram 
constructed using PROSIM software 
4, 14-16
. 
Preparation of Itraconazole Microemulsion 
The microemulsion was prepared by the spontaneous 
emulsification method. Construction of phase diagram is 
a useful approach to study the complex series of 
interactions that can occur when different components 
mixed. The formulations were prepared by initially 
dissolving the required quantity of ITZ in oil (1% drug 
is incorporated in oil).Then Surfactant and Co-surfactant 
mixer were added and the final mixture was mixed by 
vortexing until a clear solution was obtained. Finally, an 
appropriate amount of water was added to the ITZ 
solution mixture drop by drop to get microemulsion. An 
appropriate amount of water & drug was added by 
stirring the mixtures at ambient temperature. 
Optimization of ITZ Microemulsion  
A factorial design is suitable for exploring quadratic 
response surface and constructing second order 
polynomial models. The design consists of replicated 
center points and the set of points lying at the midpoint 
of the multidimensional cube that defines the region of 
interest. The non-linear quadratic model generated by 
the design in the form: 
Y = b0 + b1X1 + b2X2 + b11 X12 +b22 X22 + b12 X1X2  
Where,  
Y is Response,  
b0 is intercept, 
X1 and X2 are independent factors, 
b1 and b2 are coefficients of independent factors. 
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The coefficients with second order terms (b11 and b22) 
indicate the quadratic nature and b12 is the interaction 
term (combining effect of Independent factors). This 
study investigated the utility of a 2-factor, 3- level 
factorial design and optimization process for 
Itraconazole Microemulsion by spontaneous 
emulsification method.  Amount of oil (%) X1 and Smix 
(%) X2 were selected as the independent variables 
whereas transdermal flux (Jss) and %Q6 (amount of drug 
release after 6 hrs.) selected as dependent variables. The 
design matrix was presented in Table 1.  
Desirability Analysis 
After fitting the models & residual analysis of all three 
responses, for optimization of these responses 
simultaneously optimization techniques popularize by 
derringer and such was used. Their procedure makes use 
of desirability functions the general approach is to first 
convert each responses yi into an individual desirability 
function di that varies for the range 0 ≤ di ≤ 1, where as 
if the responses yi is at its goal or target then, di=1 , if 
the response is outside acceptable region di=0. Then the 
design variables are chosen to maximize the overall 
desirability.  
                        
Where n is a number of responses.  
Statistical software package Design expert 7.0 was used 
to design and analyze an experiment.  
Characterization of Microemulsion 
Droplet size analysis 
Formulations (ME1 to ME9) were analyzed for droplet 
size. The prepared ME was inverted twice to ensure 
complete dispersion of the formulation. The prepared 
microemulsion diluted with Water with proper dilution. 
After ensuring complete dispersion of the formulation 
the droplet size of resultant ME was determined by 
photon correlation spectroscopy that analyzes the 
fluctuation in light scattering due to the Brownian 
motion of the droplets as a function of time using a DLS 
spectrophotometer (Model DLS700, Malvern 
Electronics Company Ltd., Japan).The average diameter 
(Z-AVE) and polydispersity index (PDI) of ME were 
determined by using a Malvern (Model DLS700, 
Malvern Electronics Company Ltd., Japan) at a fixed 
angle of 90˚ and at 25˚C 14, 15, 17. 
Zeta potential Measurement 
Zeta potential of formulations (ME1 to ME9) was 
analyzed by using DLS spectrophotometer (Model 
DLS700, Malvern Electronics Company Ltd., Japan) 
Equipped with a 4.0 mW He-Ne red laser (633nm).  
pH Determination  
The pH values of prepared ME1 to ME9 were 
determined using digital pH meter (Digital pH meter-III, 
EI) standardized using pH 4 and 7 buffers before use. 
Drug content 
About 10 mg equivalent of the ME was weighed in a 
100ml volumetric flask and dissolved in 100 ml 
methanol to determine drug content. It was diluted 
appropriately and drug content was determined by 
spectrophotometrically (263nm).As a blank, the ME 
system (in the same amount as used for making test 
sample) without drug was extracted in 100 ml of 
methanol and the same was used after proper dilution. 
In-vitro skin diffusion study 
The modified diffusion cell was fabricated from 
borosilicate glass and consisted of two compartments 
i.e. receptor and donor. The cell and effective receptor 
surface area of 3.14cm
2
. The two halves of the cell were 
secured in place with the help of strong metallic clips. A 
Teflon bead of 12mm length on a magnetic stirrer stirred 
the receptor solution. The temperature of the cell 
contents was maintained at 37±1oC with the help of 
thermostat attached to the magnetic stirring assembly. A 
modified Diffusion Cell was used for evaluating drug 
release profiles semi-impermeable membrane (0.1mm 
thickness). The receptor compartment was filled with 
65ml of PBS pH 7.4 containing 10% methanol stirred by 
the use of the Teflon coated bead on a magnetic stirrer. 
The whole assembly was kept tightened with the screws 
for the cell setup. The whole assembly was kept on the 
magnetic stirrer and the temperature was maintained at 
37±1
o
C with the water jacket and at the 100rpm speed of 
magnetic bead. The withdrawal port was covered with 
the glass cork which prevents air entrapment. The 
amount of ME was applied between to the donor 
compartment to receptor compartment. The amount of 
drug released into the receptor solution was determined 
by 5ml of sample withdrawal at one hr intervals for hrs. 
The withdrawn volume was replaced with an equal 
volume of fresh buffer solution. The drug was 
release/diffuse was determined by analyzing the samples 
at 263nm 
1, 6, 8
. 
In-vitro Antifungal Activity 
In vitro antifungal studies were performed against 
Candida Albicans n Sabouraud’s agar medium by the 
agar-cup method. Suspension of C. albicans was 
inoculated in Sabouraud dextrose broth and then poured 
into a sterile Petri dish and allowed to solidify. Wells 
was done on the plate using borer of size 8 mm and1 g 
each of developed formulations containing 1% of ITZ 
was poured into the wells. These plates were kept at 
4°Cfor 1 h. After 1 h plates were incubated at 37°C±1°C 
for24 h. The zone of inhibition of ITZ released from 
prepared microemulsion was calculated in centimeters 
14
. 
Estimation of Transdermal Flux   
Amount of material flowing through unit cross section 
barrier in unit time is called Transdermal flux. 
Mathematically it is expressed as  
          
Where, 
Jss = Transdermal flux  
Q = Amount of drug transferring the membrane in time t  
A = Area of the exposed membrane in cm
2
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Comparison of Diffusion Profile by Similarity Factor 
F2  
The prepared optimized ME formulation of ITZ was 
compared with marketed formulation using Similarity 
FactorF2. CDER, FDA, and EMEA as the “logarithmic 
reciprocal square root transformation of one plus the 
mean squared difference in percent drug dissolved 
between the test and the reference products” defined the 
similarity factor (F2). Moore and Flanner give the model 
independent mathematical approach for calculating a 
similarity factor (F2) for comparison between dissolution 
profiles of a different sample. The similarity factor was 
calculated by formula to give below.  
              
 
 
        
 
 
   
 
    
      
Where n= no. of time points  
Rt = the reference profile at the time point t  
Tt = the test profile at the same point
 
Table 1: Experimental Runs & Levels of independent factors as per 3
2
 Factorial Design 
Batch  Coded Value Actual Value 
X1 X2 Oil (%) Smix (%) 
ME1 -1 -1 10 40 
ME2 0 -1 20 40 
ME3 +1 -1 30 40 
ME4 -1 0 10 50 
ME5 0 0 20 50 
ME6 +1 0 30 50 
ME7 -1 +1 10 60 
ME8 0 +1 20 60 
ME9 +1 +1 30 60 
Levels Variables 
Independent Variable Low(-1) Medium(0) High(+1) 
X1 10 20 30 
X2 40 50 60 
 
RESULTS AND DISCUSSION 
Solubility study 
The physicochemical properties of ITZ suggest that it 
has good potential for topical drug delivery. The 
important criterion for selection of materials for the 
microemulsion formulation development is that the 
components are pharmaceutically acceptable, non-
irritant and non-sensitizing to the skin. The result of 
solubility study of ITZ in various Oils, Surfactants, 
Cosurfactants was shown in Table 2. Among the 
selected oils that were screened maximum solubility of 
ITZ was found in Eucalyptus oil (10.89 mg/ml). Among 
the surfactants, Tween 20 (0.81 mg/ml) showed 
reasonable solubilizing potential for ITZ. The Co-
surfactant Methanol (0.72 mg/ml) shows the highest 
solubility of ITZ. 
Construction of pseudo-ternary phase diagrams 
The construction of pseudo-ternary phase diagrams was 
used to determine the concentration range of 
components in the existence range of microemulsion. 
The translucent microemulsion region was presented in 
phase diagrams with no distinct conversion from water-
in-oil (W/O) to oil-in-water (O/W) Microemulsions 
were observed. The rest of the region on the phase 
diagram represents the turbid and conventional 
emulsions based on visual observation. Based on 
solubility study Eucalyptus oil selected as oil, Tween-20 
selected as a surfactant, Methanol selected as co-
surfactant. In Pseudo-ternary phase diagram one axis 
represents oil phase, other represent as aqueous phase 
and third represent as surfactant & co-surfactant Mixture 
(Smix). Pseudo-ternary phase diagrams for 
Microemulsions with different ratio of Smix were 
illustrated in Figure 1. The phase diagram having 
highest microemulsion region. Hence, it was found to be 
Smix ratio 3:1 selected for preparation ME. Pseudo-
ternary phase diagram was constructed using PROSIM 
software. 
Table 2: Results of ITZ Solubility study in oils, 
surfactants, co-surfactants 
Types of 
Excipients 
Name of 
Excipients 
Solubility 
(mg/ml) 
 Distilled Water 0.00964 
Oil 
Clove oil 3.745 
Eucalyptus oil 10.89 
Peppermint oil 0.45 
IPM 1.044 
Oleic acid 5.645 
Castor oil 0.05 
Olive oil 0.028 
Cottonseed oil 0.04 
Surfactant 
Tween-80 0.81 
Tween-20 0.031 
Span-20 0.030 
Co-surfactant 
n-Butanol 0.36 
Ethanol 0.35 
Methanol 0.72 
Propylene Glycol 0.18 
PEG -400 0.30 
PEG – 600 0.27 
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Figure 1: Psudoternary Phase diagram of Eucalyptus oil, Tween 20 & Methanol containing different Smix Ratio 
(A) 1: 1 (B) 1: 2 (C) 2: 1 (D) 3: 1 
 
Characterization of Microemulsion 
Droplet size analysis & Zeta Potential Measurement 
All 9 formulations of microemulsion were subjected to 
globule size and zeta potential determination using DLS.  
Results of globule size & zeta potential determination 
were presented in Table 3. Globule size of the 
microemulsion was ranged from 8.064nm to 687.1 nm. 
Results of zeta potential were found between -1.26 mv 
to -4.20 mv. PDI of all the formulation was in between 
0.090 to 1.00. ME1, ME2, ME4, and ME5 showed lower 
globule size but simultaneously it had high PDI value 
and lower zeta potential values hence note selected as 
optimized formulation. ME7 may be selected as a more 
stable microemulsion, as it showed globule size 298.3nm 
and simultaneously had High Zeta potential -4.20 mV 
and Lower PDI value 0.090.  
Viscosity Measurement 
The viscosity of batch ME1 to ME9 was determined by 
using Brookfield viscometer. The Viscosity was 
measured using spindle no.64 at 62 rpm. The results of 
viscosity measurement were presented in Table 3. It was 
found between 34.5 cps to 106.1 cps. 
Determination of pH 
The pH values of prepared ME1 to ME9 were showed in 
Table 3. It indicated that all the batches showed pH 
Values near to the skin pH (7.01 to 7.43). Batch ME7 
showed closer pH value (7.40) to the skin pH Value. 
Hence, ME7 was selected as best microemulsion 
formulation.
 
Table 3: Results of characterization of ME1 to ME9 
Batch Particle Size (nm) PDI Zeta Potential (mV) Viscosity (cps) pH 
ME1 8.064 0.466 -2.22 34.5 7.01 
ME2 9.853 0.614 -1.52 35.2 6.89 
ME3 568.8 0.661 -1.28 38.3 6.25 
ME4 8.857 0.361 -1.88 56.2 7.25 
ME5 9.607 1.000 -1.26 59.9 6.90 
ME6 687.1 0.176 -3.00 63.7 6.31 
ME7 298.3 0.090 -4.20 96.5 7.40 
ME8 149.5 1.000 -1.67 101.6 6.59 
ME9 125.0 0.530 -2.05 106.1 6.40 
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In-vitro Diffusion study 
The diffusion of the Itraconazole from the 
microemulsion was depending on the concentration of 
oil: Smix. The release of the drug from the microemulsion 
formulations in high to low release order was described 
as below:  
ME7 > ME4 > ME1 > ME8 > ME5 > ME6 > ME9 > 
ME2 > ME3 
Where, the amounts of drug release after 6 hr were 
98.74%, 90.29%, 86.56%, 85.25%, 85.01%, 82.36%, 
81.36%, 80.25%, 79.12%, respectively. Amount of the 
drug diffused from the formulation through the diffusion 
membrane was completely related to the amounts of oil 
& Smix. ME7, ME4, ME1 had high drug release 
compared to other Microemulsions. It indicated that if 
the increase in the concentration of oil, the diffusion of 
the drug decreases. The cumulative % drug release 
profile of ME1 to ME9 was illustrated in Figure 2.  
Among all 9 Batches, ME7 showed highest drug 
diffusion (98.74%) after 6 hrs. This may be due to the 
presence of a lower amount of oil (10%) & higher 
amount of Smix (60%) which may be responsible for 
increased drug solubility and ultimately lead to higher 
drug diffusion. 
 
 
Figure 2: In-Vitro Diffusion Profile of ME1 to ME9 
In-vitro Antifungal Activity  
Anti-fungal activity of all 9 batches was performed to 
evaluate the effect of the presence of eucalyptus oil in 
Microemulsion. Zone of inhibition was recorded after an 
incubation period of 24hrs i.e. in Figure 3. All the 
formulations indicated the zone of inhibition similar to 
the marketed product. But ME7 showed a higher zone of 
inhibition comparatively to a marketed product which 
may be due to increased solubility of the drug in the 
microemulsion. Hence, ME7 was selected as best batch 
among all 9 batches and used for further evaluations. 
 
 
Figure 3: Results of Antifungal activity of ME1 to ME9 and Market Product 
 
 Optimization of ME using 3
2
 Factorial Design  
A 3
2
 Full Factorial Design was implemented to optimize 
ITZ Microemulsion using spontaneous emulsification 
method. Amount of oil (X1) and Amount of Smix (X2) 
was selected as independent variables. Transdermal Flux 
(Jss,Y1), % Q6 (% drug release after 6hrs, Y2) was 
selected as dependent variables or responses to measure 
for preparation of ITZ microemulsion. Results of 
experimental runs as per 3
2 
full factorial design and 
measured responses were depleted in Table 4. 
Responses surface curvature was examined when two 
variables were investigated at three levels. The design 
was provided the following empirical second order 
equation (Full model). 
Y = b0 + b1X1 + b2X2 + b11 X12 +b22 X22 + b12 X1X2 
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Where, 
Y was represented response, b0 was intercept, b1 and b2 
are the coefficients of main effects, b12 was the 
coefficient for the interaction term and b11 and b22 were 
the coefficients for the second order quadratic terms. 
Nonsignificant estimated coefficients were dropped 
from the full model by adopting a significance test for 
the regression coefficient. A coefficient was significant 
if P < 0.05. Design Expert 9.0 trial software was used 
for statistical optimization to plot counter & 3D 
Response surface plots. 
 
Table 4: Experimental Runs and Measured Responses as per 3
2
 Factorial Design 
Batch 
Independent Variables Responses 
X1 X2 
Transdermal Flux (Jss) 
(mg cm
2
 h
-1
) 
%Q6 (%) 
ME1 -1 -1 4.275 86.56 
ME2 0 -1 4.043 80.25 
ME3 +1 -1 3.891 78.00 
ME4 -1 0 4.413 90.29 
ME5 0 0 4.181 89.20 
ME6 +1 0 4.0716 86.79 
ME7 -1 +1 4.793 98.74 
ME8 0 +1 4.236 85.70 
ME9 +1 +1 4.100 80.65 
 
Transdermal Flux (Jss) 
Transdermal Flux (Jss) was analyzed using Design 
Expert for prepared Microemulsion. A coefficient with 
positive sign shows a synergistic effect whereas a 
coefficient with negative sign shows an antagonistic 
effect. A coefficient of independent factor X1 with a 
negative sign (-0.24) indicated that transdermal Flux 
(Jss) was change with change in amount of oil (batch 
F1, F2 and F3) similarly a coefficient of Independent 
factor X2 with a positive sign (0.15) indicated that 
amount of Smix had positive effect of transdermal Flux 
increase in value of Smix increased value of transdermal 
flux & vice versa. ANOVA result of transdermal flux 
indicated the model F-value of 20.49 implies the model 
is significant. There is only a 0.21% chance that a 
"Model F-Value" this large could occur due to noise. 
A negative value of A indicated a negative effect of 
variables on Microemulsion formulation. A positive 
value of coefficient B indicated a positive effect on Smix 
Concentration. Increased in the value of X1(A) range in 
value of microemulsion. It indicated that Smix 
concentration increased transdermal flux was increased. 
Table 4 showed Results of ANOVA & Regression 
analysis for Transdermal Flux. 
Effect of X1& X2 on transdermal flux was illustrated in 
4.
 
 
Figure 4: 3D Response Surface Plot Showing Effect of X1 and X2 on Transdermal flux (Jss) 
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Table 5: Results of ANOVA & Regression analysis for Transdermal Flux 
Source 
Sum of 
squares 
Df 
Mean 
square 
F value 
P- Value 
Prob >f 
 
Model 0.48 2 0.24 20.49 0.0021 Significant 
A- Amount of oil (X1) 0.34 1 0.34 28.83 0.0017  
B- Amount of Smix (X2 ) 0.14 1 0.14 12.16 0.0130  
Residual 0.070 6 0.012    
Cor total 0.55 8     
Std Dev 0.11 R-squared 0.8723 
Mean 4.22 Adj R-squared 0.8297 
C.V.% 2.55 Pred R-squared 0.6643 
PRESS 0.18 Adeq precision 12.525 
 
The "Pred R-Squared" of 0.6643 is in reasonable 
agreement with the "Adj R-Squared" of 0.8297. "Adeq 
Precision" measures the signal to noise ratio.  A ratio 
greater than 4 is desirable.  The ratio of 12.525 indicates 
an adequate signal.  This model can be used to navigate 
the design space.The polynomial equation generated by 
using regression analysis as described below. 
Final Equation in Terms of Code Factors: 
Transdermal Flux = +4.22 -0.24*A +0.15*B 
Final Equation in Terms of Actual Factors: 
Transdermal Flux = +4.2267-0.23633*Amount of Oil 
(X1) +0.15350  *Amount of Smix (X2) 
% Q6 
Q6 was analyzed using Design Expert for prepared 
microemulsion. A coefficient with positive sign shows a 
synergistic effect whereas a coefficient with negative 
sign shows an antagonistic effect. A coefficient of 
independent factor X1 with a positive sign (183.04) 
indicated that Q6 was decreased as the amount of oil 
was increased similarly a coefficient of independent 
factor X2 with a negative sign (69.50) indicated that Q6 
was increased as the amount of Smix was increased. 
ANOVA of %Q6 indicates the model F-value of 11.27 
implies the model is significant. There is only a 0.93% 
chance that a "Model F-Value" this large could occur 
due to noise. Values of "Prob > F" less than 0.0500 
indicate model terms are significant.In this case A, B are 
significant model terms. Values greater than 0.1000 
indicate the model terms are not significant.In this model 
coefficient of X2 (Amount of Smix %) has a p-value less 
than 0.05 that means it was considered as a significant 
term in optimization formulation.  
The combined effect of both of independent factors was 
essential to predict and achieve a targeted value of Q6. 
The positive sign of the interaction term indicated a 
favorable effect of both oil, Smix on Q6. The relationship 
between the dependent and independent variables was 
presented in Figure 5. Table 5 showed ANOVA Result& 
Regression analysis for % Q6. 
The "Pred R-Squared" of 0.5292 is in reasonable 
agreement with the "Adj R-Squared" of 0.7196."Adeq 
Precision" measures the signal to noise ratio. A ratio 
greater than 4 is desirable. The ratio of 9.237 indicates 
an adequate signal. This model can be used to navigate 
the design space.The polynomial equation generated by 
using regression analysis as described below. 
Final Equation in Terms of Code Factors: 
%Q6= +85.90-5.52*A+3.40*B 
Final Equation in Terms of Actual Factors: 
% Q6= +85.90444-5.52333*Amount of 
oil(X1)+3.40333*Amount Smix(X2)
 
 
Figure 5: 3D Response Surface Plot Showing Effect of X1 and X2 on %Q6 
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Table 6: Results of ANOVA & Regression analysis for %Q6 
Source Sum of 
squares 
Df Mean 
square 
F value P- Value 
Prob >f 
 
Model 252.54 2 126.27 11.27 0.0093 Significant 
A-Amount of oil (X1) 183.04 1 183.04 16.63 0.0068  
B-Amount of Smix (X2 ) 69.50 1 69.50 6.20 0.0472  
Residual 67.24 6 11.21    
Cor total 319.78 8     
Std Dev 3.35 R-squared 0.7897 
Mean 85.90 Adj R-squared 0.7196 
C.V.% 3.90 Pred R-squared 0.5292 
PRESS 150.56 Adeq precision 9.237 
 
Desirability Analysis: 
The design expert software package was used to 
optimize the Microemulsion formulation with respect to 
maximum Transdermal flux and maximum %Q6. 
Keeping 2 independent variables within the range, 
which were found by experimental analysis constraints 
for the optimization & desirability was shown in Table 
7. 
We set weight for this individual desirability equal to 
unity. It was observed that is this analysis the medium 
consisting of the amount of oil and amount of Smix was 
found to predict optimize batch with overall highest 
desirability 0.805 as compared to other formulation. 
Table 7: Constraints for optimization and Desirability Analysis 
Constraints 
Name Goal Lower 
Limit 
Upper 
Limit 
Lower 
Weight 
Upper 
Weight 
Importance 
Amount of Oil (X1) is in range -1 1 1 1 3 
Amount of Smix (X2) is in range -1 1 1 1 3 
Transdermal Flux Maximize 3.891 4.793 1 1 3 
% Q6 Maximize 78.25 98.74 1 1 3 
 
Table 8: Solutions for optimization of Batch according to Desirability analysis 
Solutions 
Number Amount of Oil (X1) 
Amount of 
Smix (X2) 
Transdermal 
Flux 
%Q6 Desirability  
1 -1 1 4.6125 94.89333 0.805 Selected 
2 -0.98 1 4.60858 94.7365 0.721  
3 -1 0.88 4.59453 94.4327 0.785  
 
It was arbitrarily decided for the selection of optimized 
batch, optimized batch had higher Transdermal flux and 
% Q6. On the basis of constraints for optimization 
batch, ME7 was selected as an optimized batch for ITZ 
Microemulsion. To validate the evolved mathematical 
models, two checkpoints were selected. The observed 
and predicted values for checkpoint analysis were 
presented in Table 9. 
Good correlation between observed and predicted values 
of measured responses. Hence, it might be concluded 
that the evolved model might be used for theoretical 
prediction of responses within the factor space. 
Table 9: Check Point Analysis of Microemulsion 
 
Batch 
 
X1 
 
X2 
Measured Responses 
Transdermal Flux %Q6 (%) 
Observed Predicated Observed Predicated 
FC 1 0.5 0.25 4.21 4.22 85.71 85.713 
FC 2 0.25 0.5 4.23 4.18 85.93 85.94 
 
Batch ME7 was selected as optimized microemulsion 
loaded with Itraconazole and It was further used to 
prepare Aerosol formulation containing microemulsion. 
Comparison of Diffusion Profile by Similarity Factor 
F2  
Optimized microemulsion batch (ME7) and marketed 
formulation of Itraconazole (ITASPOR) was compared 
using model-independent method. in vitro diffusion 
study data were compared in this study. Comparison of 
diffusion profile of ME7 and ITASPOR was showed in 
Figure 6. It indicated F2 value 50.92. For similarity 
between in vitro diffusion of both formulations value of 
F2 must be closer to the 100. In this comparison, this 
value was far away from 100. Hence, it was concluded 
that there is no similarity observed in the diffusion 
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profile. This suggested that there was a change in the 
diffusion profile of the optimized batch. Therefore, 
formulation of microemulsion for Itraconazole 
successfully increased solubility, permeation, and 
diffusion of the drug from the microemulsion. 
 
Figure 6: Comparison of In-Vitro Diffusion Profile of 
ME7 and ITASPOR (INTAS) 
CONCLUSION 
For preparation of microsimulation for itraconazole 
various oils, surfactants, and co-surfactants were 
screened via drug solubility study and a drug having 
maximum solubility selected for microemulsion 
preparation. The solubility of the drug was found higher 
in Eucalyptus oil (10.89mg/ml), Tween-20(0.81mg/ml), 
Methanol (0.72mg/ml) and Hence, selected for 
preparation of microemulsion. The pseudoternary phase 
diagrams were plotted to find out suitable 
microemulsion region mixture of surfactant. Surfactant: 
Co-surfactant (Smix) was prepared in the ratio of 1:1, 1:2, 
2:1 and 3:1.  The various proportion of oil: Smix was 
prepared i.e 1 to 9 and vice versa. Results of phase 
diagram revealed that stable microemulsion region was 
found oil: Smix at 9:1 (Smix: Oil) ratio where it contains 
Smix ratio 3:1. The microemulsion was optimized using 
full factorial design. From all 9 batches of the ME7 
Microemulsion was selected as an optimized batch, it 
showed maximum Transdermal Flux (4.739 mg cm
2
h
 -1
), 
%Q6 (98.74%). The desirability study was also revealed 
that ME7 has maximum desirability i.e. 0.805. in 
conclusion, Microemulsion successfully increased the 
permeation of the Itraconazole. Batch ME7 was selected 
as optimized microemulsion loaded with Itraconazole. 
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